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Abstract
Paratuberculosis has been assessed according to the criteria of the Animal Health Law (AHL), in
particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of
paratuberculosis to be listed, Article 9 for the categorisation of paratuberculosis according to disease
prevention and control rules as in Annex IV and Article 8 on the list of animal species related to
paratuberculosis. The assessment has been performed following a methodology composed of
information collection and compilation, expert judgement on each criterion at individual and, if no
consensus was reached before, also at collective level. The output is composed of the categorical
answer, and for the questions where no consensus was reached, the different supporting views are
reported. Details on the methodology used for this assessment are explained in a separate opinion.
According to the assessment performed, paratuberculosis can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL. The disease would comply with the criteria
in Sections 3, 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and control
rules referred to in points (c), (d) and (e) of Article 9(1). The animal species to be listed for
paratuberculosis according to Article 8(3) criteria are several species of mammals and birds as
susceptible species and some species of the families Bovidae, Cervidae and Leporidae as reservoirs.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on paratuberculosis according to the
criteria of the AHL articles as follows:
• Article 7: paratuberculosis proﬁle and impacts
• Article 5: eligibility of paratuberculosis to be listed
• Article 9: categorisation of paratuberculosis according to disease prevention and control rules
as in Annex IV
• Article 8: list of animal species related to paratuberculosis.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of paratuberculosis according to the Article 7 criteria of the
AHL and related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)),
based on the information contained in the fact-sheet as drafted by the selected disease scientist (see
Section 2.1 of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
Paratuberculosis is a chronic intestinal infection caused by Mycobacterium avium subsp.
paratuberculosis (MAP). The disease was originally described as a peculiar case of bovine tuberculosis
more than a century ago (Johne and Frothingham, 1895), but was later characterised as an
independent entity when B. Bang infected calves with intestinal smears of diseased cows (Bang,
1906). MAP primarily affects domestic and wild ruminants and has a worldwide distribution (Sweeney,
2011). The main clinical features are: initially intermittent diarrhoea that becomes persistent and
profuse. It leads to increased loss of plasma proteins, malabsorption of nutrients and water and
therefore weight loss and declining milk production.
The progressing MAP infection has severe consequences in the subclinically infected and, especially,
the clinically affected animals, leading to reduced milk yield (Lombard et al., 2005; Raizman et al.,
2007), weight loss (Benedictus et al., 1987; Hutchinson, 1996), infertility (Johnson-Ifearulundu et al.,
2000; Kostoulas et al., 2006a) and eventually premature removal from the herd. MAP is also suspected
of being involved in the aetiology of Crohn’s disease (CD) (e.g. Uzoigwe et al., 2007). This potential
implication, if conﬁrmed, adds importance to control efforts aiming to prevent transmission through
milk consumption and other products of animal origin.
MAP control has been largely hampered by the absence of diagnostic tests that can effectively
detect animals at the early infection stages. The sensitivity for most of the existing humoral tests
increases with disease progression and only animals in the advanced stages are effectively identiﬁed
through testing. Beaver et al. (2017) have conﬁrmed earlier work by Van Schaik et al. (2003a,b)
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demonstrating that faecal shedding generally precedes a positive humoral response by showing that
spikes in faecal shedding of MAP predicted high serum enzyme-linked immunosorbent assay (ELISA)
values up to 2 months later (Van Schaik et al., 2003b; Beaver et al., 2017). Various classiﬁcation
systems have been proposed to describe the various stages of MAP infection. Most of them depend on
disease progression. For example, Whitlock and Buergelt (1996) described four stages: (i) silent
infection, (ii) subclinical disease, (iii) clinical disease and (iv) advanced clinical disease (Whitlock and
Buergelt, 1996). Animals in the ﬁrst stage remain undetected with standard diagnostics, while a small
percentage (15–25%) of animals in the second stage can be detected. Most of the animals in the third
and fourth stage test positive.
An alternative classiﬁcation considers the different stages of MAP infection in combination with the
purpose of testing (i.e. prevalence estimation, control, eradication, etc.) and can be more helpful for a
control-oriented approach (Nielsen and Toft, 2008). Animals can be (i) infected that carry MAP
intracellularly and some of them control the infection, whereas others proceed to next stages; (ii)
infectious that shed sufﬁcient load of MAP to infect a susceptible herd mate; (iii) affected with chronic
or intermittent diarrhoea and/or suboptimal productivity. MAP-infected animals are primarily of
relevance for prevalence estimation; MAP-infectious animals when transmission should be avoided in a
control scheme and MAP affected when the target is animals that should be removed from a herd
because of their poor productivity and hence negative input.
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
An extensive but not exhaustive list of susceptible animal species (from which MAP has only been
isolated, and species from which MAP has been isolated and clinical signs associated with MAP
infection have been reported) is shown in Table 1. Among domestic ruminants, cattle, sheep and goat
are commonly affected (Nielsen and Toft, 2009), while it has also been reported in farmed zebu cattle
(Fernandez-Silva et al., 2014), llamas (Belknap et al., 1994), alpacas (Ridge et al., 1995), fallow and
red deer (Machackova et al., 2004). Natural infections are reported from mouﬂon in Austria and the
Czech Republic, and chamois in Austria. Studies of Cervidae indicate that at least fallow deer can be
infected with MAP subsequent to natural exposure, as demonstrated by histopathology. MAP has also
been isolated from fallow deer, red deer and roe deer in various countries of Europe (Nebbia et al.,
2000; Machackova et al., 2004; Deutz et al., 2005; Carta et al., 2013), but histopathological
investigations were not carried out in these studies. Hence, although carriage was demonstrated,
disease may not have been present. Tryland et al. (2004) reported serological responses against MAP
in moose in Norway, but methods to detect MAP or pathological changes were not applied. Wild boars
have also tested positive for MAP in tissue culture (Pribylova et al., 2011a; Carta et al., 2013), but in
neither of the studies were histopathological changes described.
Among lagomorphs, MAP infections have been established in rabbits, but there is insufﬁcient data
to determine if infections can occur in hares. MAP infection can be maintained in a wild lagomorph
population (Judge et al., 2006). The high proportion of infected foxes may be a result of the high
number of infected rabbits, which may be consumed by the foxes. Among free-ranging carnivores,
only a few studies have been carried out. It is highly likely that MAP infections occur in fox, but less
certain whether the infection can be established in other carnivore species. Only a limited number of
rodent-studies on MAP infections have been carried out, which is surprising considering their generally
huge population size and often close proximity to farmed animals. It is not possible to determine
whether natural infections occur among rodents based on these studies (Florou et al., 2008).
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Table 1: Farmed (F) or free-ranging (R) animal species from which Mycobacterium avium subsp.
paratuberculosis (MAP) has been isolated (I) and susceptible species (S) from which MAP
has been isolated and clinical signs associated with paratuberculosis have been reported.
Reporting of experimental (E) and/or natural (N) MAP infection is also listed as well as the
extinction risk of each species according to the red list of the International Union for
Conservation of Nature (IUCN)
F/R Order Family Species I,S E/N(a) IUCN(b) Reference
F Artiodactyla Bovidae Cattle (Bos taurus) S E,N NE Nielsen and
Toft (2009)
F Goats (Capra aegagrus hircus) S E,N NE
F Sheep (Ovis aries) S E,N NE
F Zebu cattle (Bos indicus) S N NE Chiodini et al.
(1984b)
F American bison (Bison bison) S N NT Buergelt and
Ginn, 2000)
F Camelidae Llama (Lama glama) S N LC Kramsky et al.
(2000)
F Alpaca (Vicugna pacos) S N NE Ridge et al.
(1995)
F Cervidae Fallow deer (Dama dama) S N LC Machackova
et al. (2004)
F Red deer (Cervus elaphus) S N LC
F Elk (Cervus elaphus canadensis) S N LC Manning et al.
(1998)
R Aves Buzzard (Buteo buteo) I N LC Beard et al.
(2001b)
R Crow (Corvus corone) I N LC
R Feral pigeon (Columbia livia) I N –
R House sparrow (Passer
domesticus)
I N LC
R Jackdaw (Corvus monedula) I N LC
R Pheasant (Phasianus colchicus) I N LC
R Rook (Corvus frugilegus) I N LC
R Wood pigeon (Columba
palumbus)
I N LC
R European starling (Sturnus
vulgaris)
I N LC Corn et al.
(2005)
R Common snipe (Gallinago
gallinago)
I N LC
R Chicken (Gallus gallus) S E LC Larsen et al.
(1972)
R Diamant sparrow (Emblema
guttata)
S N – Miranda et al.
(2009)
R Carnivora Canidae Fox (Vulpes vulpes) S N LC Beard et al.
(2001b)
R Dog (Canis lupus) S N LC Kukanich et al.
(2013)
R Felidae Feral cat (Felis catus) I N –
R Mephitidae Stripen skunk (Mephitis
mephitis)
I N LC Corn et al.
(2005)
R Mustelidae Badger (Meles meles) I N LC Daniels et al.
(2003)
R Ursidae European brown Bear (Ursus
arctos)
I N LC Kopecna et al.
(2006)
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F/R Order Family Species I,S E/N(a) IUCN(b) Reference
R Stoat (Mustela erminea) I N LC Daniels et al.
(2003)
R Weasel (Mustela nivalis) I N LC
R Procyonidae Raccoon (Procyon lotor) I N LC Corn et al.
(2005)
R Lagomorpha Leporidae Hare (Lepus spp.) I N – Beard et al.
(2001a)
R European brown hare (Lepus
europaeus)
I N LC Corn et al.
(2005)
R Mountain hare (Lepus timidus) S N LC Deutz et al.
(2005)
R Rabbit (Oryctolagus cuniculus) S E,N NT Greig et al.
(1999)
R Eastern cottonail (Sylvilagus
ﬂoridanus)
I N LC Corn et al.
(2005)
R Rodentia Bank vole (Clethrionomys
glareolus)
I N LC Beard et al.
(2001b)
R Field vole (Microtus agrestis) I N LC
R House mouse (Mus domesticus) I N LC
R Mouse (not further speciﬁed)
(Mus spp.)
S E – Deutz et al.
(2005)
R Wood mouse (Apodemus
sylvaticus)
I N LC Beard et al.
(2001a)
R Yellow-necked mouse
(Apademus ﬂavicollis)
S N LC Deutz et al.
(2005)
R Rat (Rattus norvegicus) I N LC Florou et al.
(2008)
R Hispid cotton rat (Sigmodon
hispidus)
I N LC Corn et al.
(2005)
R Norway rat (Blarina brevicauda) I N LC Corn et al.
(2005)
R Hamster (Mesocricetus spp.) S E – Larsen and
Miller (1978)
R Guinea pig (Cavia porcellus) I E – Merkal et al.
(1982)
R Artiodactyla Bovidae Water buffalo (Bubalis bubalis) S N EN Sivakumar
et al. (2006)
R Bison (Bison bison) S E,N NT Buergelt and
Ginn (2000)
R Alpine ibex (Capra ibex) S N LC Ferroglio et al.
(2000)
R Chamois (Rupicapra rupicapra) S N LC Deutz et al.
(2005)
R Yak (Bos grunniens) S N NE Geilhausen
(2002)
R Rocky mountain goat (Oreamos
americanus)
S N NE Williams et al.
(1983)
R Pygmy goat (Capra hircus) S E,N NE Ayele et al.
(2001)
R Dwarf goats (Capra aegagrus
hircus)
S N NE Manning et al.
(2003)
R Stone buck (Capra aegagraus
ibex)
S N NE Chiodini et al.
(1984a)
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F/R Order Family Species I,S E/N(a) IUCN(b) Reference
R Mouﬂon sheep (Ovis orientalis) S N VU Pribylova et al.
(2011b)
R Bighorn sheep (Ovis
canadensis)
S E,N LC Greig et al.
(1999)
R Aoudad (Barbary sheep)
(Ammotragus lervia)
S N VU Ayele et al.
(2001)
R Cameroon sheep (Ovis aries
cameroon dwarf)
S N NE
R Antelope kudu (Tragelaphus
strepsiceros)
S N LC
R Saiga antelope (Saiga tatarica) S N CR Dukes et al.
(1992)
R Camelidae Bactrian camel (Camelus
bacterianus)
S N CR Ayele et al.
(2001)
R Dromedary camel (Camelus
dromedarius)
S N – Amand (1974)
R Guanacos (Lama guanicoe) I N LC Salgado et al.
(2009)
R Cervidae Fallow deer (Dama dama) S N LC Marco et al.
(2002)
R Red deer (Cervus elaphus) S E,N LC Tryland et al.
(2004)
R Roe deer (Capreolus capreolus) S N LC Tryland et al.
(2004)
R Sika deer (Cervus nippon) I N LC Ayele et al.
(2001)
R Axis deer (Axis axis) I N LC
R Key deer (Odocoileus
virginianus clavium)
S N NE Quist et al.
(2002)
R Mule deer (Odocoileus
hemionus)
S E,N LC Williams et al.
(1983)
R Pudu (Pudu pudu) I N – Ayele et al.
(2001)
R White-tailed deer (Odocoileus
virginianus)
S E,N LC Williams et al.
(1983)
R Moose (Alces alces) S N LC Tryland et al.
(2004)
R Reindeer (Rangifer tarandus) I N VU Tryland et al.
(2004)
R Elk (Cervus canadensis) S N NE Ayele et al.
(2001)
R Tule elk (Cervus elaphus
nannodes)
S N LC
R Rocky mountain elk (Cervus
elaphus nelsoni)
S E,N – Williams et al.
(1983)
R Suidae Wild boar (Sus scrofa) I N LC Boadella et al.
(2011)
R Pigs (Sus spp.) I E –
R Didelphimorphia Didelphidae Opossum (Didelphis virginiana) I N LC Corn et al.
(2005)
R Cingulata Dasypodinae Armadillo (Dasypus
novemcinctus)
I N LC
R Perissodactlya Equidae Pygmy ass (Equus asinus f.
dom.)
S N – Ayele et al.
(2001)
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Reservoir animal species
Wildlife and domestic species can serve as potential reservoirs since interspecies transmission has
been documented. However, their potential role in the epidemiology of paratuberculosis depends on
(i) whether paratuberculosis is endemic in a region or not (i.e. under endemic disease conditions
within herd/ﬂock transmission is the main way of disease persistence) and (ii) the husbandry type (i.e.
whether systems allow for interface between domestic and wildlife carriers through, for example,
co-grazing). Stevenson et al. (2009) genotyped 164 MAP isolates from seven European countries
representing 19 different host species, and provided evidence of interspecies transmission between
wildlife and domestic ruminants and among wildlife species, adding further support to the reservoir
role of wildlife (Stevenson et al., 2009). Only ruminants (Bovidae, Cervidae) and lagomorphs show
evidence of disease as determined by the presence of gross or microscopic lesions with associated acid
fast bacteria, thus species have the capacity to excrete MAP and spread disease to other susceptible
species primarily through further faecal contamination of the environment, so potentially, they could
constitute wildlife reservoirs. By deﬁnition, to constitute a wildlife reservoir the infection would need to
be sustained within the species population. Evidence is available for vertical and horizontal
transmission within natural rabbit populations which could contribute to the maintenance of Map
infections within such populations (Stevenson et al., 2009). Rabbits can also serve as a reservoir in the
UK due to the high prevalence of MAP infection and the high excretion rates (Greig et al., 1999; Judge
et al., 2006).
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
A recent review aiming to identify potential sources of MAP exposure for humans (Waddell et al.,
2016) found 148 research papers on the prevalence and/or presence of MAP in farmed, pets and wild
animals. Earlier, Nielsen and Toft (2009) summarised the prevalence of paratuberculosis for dairy
cattle, sheep and goats in Europe. The latter authors concluded that, for each species, prevalence
estimates at the animal level are not comparable. Indeed, the use of different tests among studies that
targeted different conditions, lack of knowledge on the accuracy of the used diagnostic tests in several
studies, differences in the source populations – and hence likely differences in the distribution of the
various infections stages within these populations – and ﬁnally variable sampling designs and poor
F/R Order Family Species I,S E/N(a) IUCN(b) Reference
R Horses (Equus ferus caballus) I E – Larsen et al.
(1972)
F Mules (Equus mule) S E – Chiodini et al.
(1984a)
R Primates (Non-human) Mandrill (Papio sphinx) S N – Zwick et al.
(2002)
R Stumptail macaque (Macaca
arctoides)
S N VU McClure et al.
(1987)
R Common marmoset (Callithrix
jacchus)
S N LC Fechner et al.
(2017)
R Rhesus macaques (Macaca
mulatta)
S N LC Singh et al.
(2011)
R Cottontop tamarins (Sanguinus
oedipus)
S N CR Munster et al.
(2013)
R Black-and-white ruffed lemurs
(Varecia variegata)
S N CR Munster et al.
(2013)
R Oligochaeta Lumbricidae Earthworms (Lumbricus spp.) I N – Fischer et al.
(2004)
(a): Hines et al. (2007) provided an extensive review and proposed guidelines for experimental challenge models of MAP infection.
(b): NE: not evaluated; LC: least concerned; NT: near threatened; VU: vulnerable; EN: endangered; CR: critically endangered.
An explicit description of these terms can be found at: http://www.iucnredlist.org/about/introduction
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reporting do not allow for a direct comparison of the prevalence estimates. An extensive list of the
apparent and true prevalence estimates at the animal level is given in Tables 2, 3, 4 and 5. The
apparent prevalence is deﬁned as the number of test-positive among tested subjects, whereas the true
prevalence is based on a conversion correcting the apparent prevalence for the diagnostic sensitivity
and diagnostic speciﬁcity (Houe et al., 2004).
Recent work on the within herd dynamics of MAP infection in dairy cattle (Al-Mamun et al., 2016)
assumed that latently infected animals progress to low shedders and low shedders to heavy shedders
with a yearly incidence rate of 0.47 and 0.28, respectively (Van Schaik et al., 2003a). The proportion
of calves infected at birth from latently infected, low-shedding and high-shedding animals is estimated
to be 0.15 (Sweeney et al., 1992), 0.15 and 0.17 (Crossley et al., 2005), respectively. In another
study, the proportion of infected cows with detectable MAP-speciﬁc IgG antibodies increased from
0.33, for cows 2 years of age, to 0.94 for cows 5 years of age (Nielsen et al., 2013). However, it
should be noted that most of the aforementioned estimates depended on the opinion of experts due
to the scarcity of valid data on the duration of the latent infection period. Studies that determine the
age-speciﬁc proportion of detectable infected animals can be used to provide indirect estimates of the
age-speciﬁc incidence rate for paratuberculosis and thus insight in the infection dynamics of MAP.
MAP prevalence in sheep worldwide is unknown as the disease is not notiﬁable in many countries
and the study of MAP in species other than cattle has relatively low priority. However, prevalence
varies between countries and geographical regions ranging from 2% to 32% of sheep ﬂocks affected
(Begg and Whittington, 2010). MAP has been diagnosed in sheep in the southern hemisphere in
Australia, New Zealand and South Africa, and in the northern hemisphere in Great Britain, Norway,
Austria, Greece, Spain, Portugal, Morocco and Jordan (Windsor, 2015).
In goats, MAP had been diagnosed in most goat rearing/farming countries including Austria, France,
Portugal, Spain, Greece, Great Britain, Croatia, Norway, Switzerland, Turkey, South Africa, Australia New
Zealand, Canada, the USA and Chile. The disease resembles that in sheep and it appears that prevalence
may be increasing but prevalence estimates vary widely (Djønne, 2010; Windsor, 2015).
There have been a few isolated reports of paratuberculosis in deer prior to 1970, but since then it
has been reported frequently in many countries in a range of deer species in the wild and in parks, zoos
and enclosures. It has also been diagnosed on deer farms in the UK, Ireland, Denmark, Germany and
Belgium, Hungary, Asia, Canada, the USA, Argentina, Australia and New Zealand. Serological
surveillance for paratuberculosis on 627 of New Zealand’s deer farms has been carried out since 2000,
using blood samples submitted as part of the national tuberculosis eradication scheme indicate a
national herd infection prevalence of approximately 63%. A non-random sample of 115 New Zealand
deer herds of unknown infection status reported in 2006 that 43% had pooled faecal samples
culture-positive for MAP (Mackintosh and Grifﬁn, 2010). By passive surveillance, Mackintosh et al.
(2004) estimated approximately 6% of herd prevalence of the infection in farmed deer in New Zealand
(Mackintosh et al., 2004). MAP infection was identiﬁed in over 600 farms by the examination of suspect
‘tuberculosis’ lesions in deer slaughtered plants, thus the true prevalence is expected to be higher.
Concerning other ruminant species, paratuberculosis has been reported in riverine buffalo
(Bubalus bubalis) in India, where the prevalence of infection was over 40% in some populations, and in
Italy with a low prevalence; it has also been reported widely in many populations of camels in Asia, the
Middle East, Africa and the former Soviet Union. The disease appears to be uncommon in llamas but has
been occasionally reported in alpacas in Australia, the UK and New Zealand (Mackintosh and Grifﬁn,
2010).
Table 2: Animals that tested positive (T+) of the animals tested (N), apparent (AP) and true
prevalence (TP) of MAP in cattle by region/country
Country Region Type of test N T+ AP (%) TP (%) Reference
Austria All ELISA 756 144 19.0 100.0 Dreier et al.
(2006)
Austria Four regions ELISA 11,028 664 6.0 47.0 Gasteiner
et al. (1999)
Belgium ELISA 13,317 116 0.87
(0.71,1.03)
0.0 Boelaert et al.
(2000)
France Yonne ELISA 8,793 292 3.3 22.0 Petit (2001)
Germany Saxony ELISA 3,454 151 4.4 31.0 Donat et al.
(2005)
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Country Region Type of test N T+ AP (%) TP (%) Reference
Germany Arnsberg ELISA 536 79 14.7 98.0 Bottcher and
Gangl (2004)
Germany Arnsberg Tissue culture 517 7 1.35
Germany Bavaria ELISA 2,748 41 1.5 0.0
Germany Bavaria ELISA 2,748 25 0.15 6.0
Germany Bavaria ELISA 2,748 662 24.1 100.0
Italy Latium ELISA 19,627 472 2.4 100.0 Lillini et al.
(2005)
Italy Lombardia ELISA 38,478 982 2.55 Arrigoni et al.
(2008)
Italy Veneto ELISA 27,135 949 3.5 17.0 Robbi et al.
(2003)
Italy Umbria ELISA 788 44 5.6 9.7
(7.0; 12.4)
Cenci-Goga
et al. (2010)
Norway ELISA 9,456 728 7.7 83.0 Tharaldsen
et al. (2003)
Rep. of
Ireland
Imported ELISA, Faecal
culture
225
221
8
9
3.6
4.0
19.0 O’Doherty
et al. (2002)
Slovenia All ELISA 11,513 47 0.41 0.0 Ocepek et al.
(2002)
Slovenia All ELISA 12,082 140 1.16 0.0
Slovenia All ELISA 38,469 1305 3.4 16
Slovenia All ELISA 9,388 41 0.4 3.0
Spain ELISA 61,069 1374 2.53 (Dairy)
1.59 (Beef)
2.44 (Mixed)
2.25 (Total)
3.02 (Dairy)
2.07 (Beef)
3.84 (Mixed)
2.95 (Total)
Dieguez et al.
(2007)
Sweden All Faecal culture 4,000 0 0.0 0.0 Sternberg
and Viske
(2003)
Switzerland Plat. de Diesse ELISA 565 29 5.1 30 Meylan et al.
(1995)
Switzerland All ELISA 1,663 12 0.7 0.0 Stark et al.
(1997)
Switzerland F57 PCR 101 20 19.8 Bosshard
et al. (2006)
The
Netherlands
All ELISA 15,822 400 2.5 2.0 Muskens
et al. (2000)
Turkey IS900 PCR 96 0 0.0 Ikiz et al.
(2005)
Turkey Elazig IS900 PCR 500 25 5.0 Cetinkaya
et al. (2000)
United
Kingdom
SW England IS900 PCR 1,297 46 3.5 (2.6; 4.7) Cetinkaya
et al. (1996)
United
Kingdom
SW England IS900 PCR of
T+ from IS900
PCR
1,297 34 2.6 (1.8; 3.6)
Brazil ELISA 128 41 32 Ristow et al.
(2007)
Brazil Culture 24 10 41
Canada Nova Scotia ELISA 814 27 3.3 Tiwari et al.
(2006)
Canada Prince Edward
Island
ELISA 816 11 1.3
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Country Region Type of test N T+ AP (%) TP (%) Reference
Canada New Brunswick ELISA 804 23 2.9
Canada Ontario ELISA 1,530 34 2.2
Canada Manitoba ELISA 1,204 54 4.5
Canada Saskatchewan ELISA 1,530 41 2.7
Canada Alberta ELISA 1,500 105 7.0
Canada Alberta Tissue culture 984 158 16.1 McKenna
et al. (2004)
USA Georgia ELISA 637 61 9.58 Pence et al.
(2003)
USA Florida ELISA 4,491 768 17.1 Braun et al.
(1990)
USA Wisconsin ELISA 4,990 364 7.3 4.79 Collins et al.
(1994)
USA Michigan ELISA 3,886 268 6.9 Johnson
et al. (2001)
USA 20 States 31,745 794 2.5 Wells (1996)
Egypt Faecal culture,
PCR,
Microscopic
examination
160 75 50 Salem et al.
(2005)
ELISA: enzyme-linked immunosorbent assay; PCR: polymerase chain reaction.
Table 3: Animals that tested positive (T+) of the animals tested (N), apparent (AP) and true
prevalence (TP) of MAP in sheep by region/country
Country Region Test N T+ AP (%) TP (%) Reference
Austria All ELISA 169 1 0.6 0.0 Khol et al. (2006)
Austria All Tissue culture 169 1 0.6
Cyprus ELISA 3,429 340 9.9 (8.9; 10.9) 24.6 Liapi et al. (2011)
Norway All Faecal culture 369 1 0.3 0.0 Mork et al. (2003)
ELISA: enzyme-linked immunosorbent assay.
Table 4: Animals that tested positive (T+) of the animals tested (N), apparent (AP) and true
prevalence (TP) of MAP in goats by region/country
Country Region Test N T+ AP (%) TP (%) Reference
Austria All Faecal/Tissue
culture
80 0 0.0 Khol et al. (2006)
Austria All ELISA 80 0 0.0 0.0
Cyprus ELISA 4,582 362 7.9 (7.2; 8.7) 23.1 Liapi et al. (2011)
Greece Milk ELISA 1,200 10.0 Angelidou et al. (2014)
Norway All Faecal culture 662 7 1.1 0.0 Mork et al. (2003)
Portugal Lisbon ELISA 2,351 41 1.7 Mendes et al. (2004)
ELISA: enzyme-linked immunosorbent assay.
Table 5: Animals that tested positive (T+) of the animals tested (N), apparent (AP) and true
prevalence (TP) of MAP in mixed sheep and goat ﬂocks by region/country
Country Region Test N T+ AP (%) TP (%) Reference
Portugal Lisbon ELISA 2351 41 1.7 Mendes et al. (2004)
Slovenia All ELISA 12578 440 3.5 Ocepek et al. (2002)
ELISA: enzyme-linked immunosorbent assay.
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Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
The case-morbidity rate is not known. Partly, it is not known if cure can take place or some animals
are naturally resistant, partly the long incubation period makes assessment challenging while many
infected animals are culled before a causative diagnosis is made, but culling is based on impact of the
disease agent (e.g. reduced milk yield). Therefore, the case-morbidity rate considering the natural life
of domestic animals can be higher than what can be observed in their production life.
At any point in time, it is believed that 50–70% of MAP infected animals are undetectable; a
fraction referred to as the invisible part of the ‘iceberg’ (Whitlock and Buergelt, 1996). Recently,
Schukken et al. (2015) in a long-term follow-up study, including of test negative apparently healthy
dairy cows at routine slaughter, from three infected dairy farms demonstrated that the prevalence of
positive samples was 1.4% for serological samples, 2.2% in faecal samples and 16.7% in tissue
samples.
A common feature of mycobacterial infections is the long latent infection period. Under endemic
disease conditions, most animals acquire MAP early in their life. Infected animals may not experience
progression of the infection during their productive life because they are resistant or will be
prematurely removed. Hence, animals in a herd can be: uninfected or potentially latently infected
animals where infection will never evolve; latently infected where infection will evolve within their
expected life-time; and animals where the infection is progressing with a predominant
anti-inﬂammatory or humoral immune response (Nielsen, 2009).
Sheep, goats, deer and South American camelids presents with ill thrift and progressive chronic
weight loss as the primary clinical sign of disease with poor production; affected animals may also
display exercise intolerance and in only 10–20% of clinical cases will intermittent soft faeces, clumping
of faces or even persistent diarrhoea be noted in the end stages of the disease although most sheep
that die of Johne’s disease (JD) have normal faecal pellets. In a study of 50 sheep with clinical JD,
most were emaciated; half had normal faecal pellets; 30% had soft-formed faeces; and 20% had
severe diarrhoea (Stehman, 1996; Smith, 1998; Begg and Whittington, 2010; Windsor, 2015).
The disease in camels may have a more rapid course than in cattle, with death occurring after
4–6 weeks’ illness. In Bactrian camels, the disease was most severe in 3–5-year-old animals. Clinical
disease has occurred in 12–24-month-old alpacas as well as in adults, with signs of diarrhoea, weight
loss and hypoproteinaemia. As with other species, necropsy showed emaciation, thickened intestines
and enlarged mesenteric lymph nodes (Mackintosh and Grifﬁn, 2010).
The pathogenesis of MAP infection in cervids is different from that in other ruminant species. Deer
appear to be highly susceptible to MAP infection and show clinical evidence of disease and severe
pathology at an earlier age than other ruminants. Clinical disease has been reported in fawns and
yearlings of white-tailed deer, sika and fallow deer, red deer and North American elk. In spite of this,
only a small proportion of deer exposed to MAP develop clinical disease (Mackintosh and Grifﬁn, 2010).
MAP infection in deer causes long standing infection and minimal mortality (Mackintosh et al., 2004).
In farmed deer, two clinical syndromes of JD have been recognised: sporadic cases occurring in
mixed-age class with yearly incidence of 1–3%, usually low morbidity (< 1%) and high mortality
(~ 100%); and outbreaks involving young deer (8–15 months of age) up to 20% of a group with a
clinical progression to emaciation and death in few weeks. However the prevalence of subclinical MAP
infection is not known in farmed deer, but up to 10% of apparently healthy deer from infected farms
had macroscopic evidence of infection at slaughter thus is highly probable that the prevalence is much
higher and many subclinical infected deer do not report any macroscopic evidence of infection
(Mackintosh et al., 2004).
Mortality
Parameter 3 – Case-fatality rate
There is scarcity of valid estimates on the true mortality rate due to the long latent infection period,
the absence of sensitive tests and hence our inability to estimate the true prevalence of infection (and
therefore the denominator of mortality and other rates). A study conducted on 12 sheep farms in New
South Wales, Australia identiﬁed the disease mortality rate in 2003 as 8% (Windsor, 2015). Most
affected goats, if not culled, go into stage four and develop advanced clinical disease, leading to death
(Djønne, 2010). The disease in camels may have a more rapid course than in cattle, with death
occurring after 4–6 weeks’ illness (Djønne, 2010; Mackintosh and Grifﬁn, 2010).
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3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
The human implications of paratuberculosis depend on the resolution of the question on whether
MAP is involved in the aetiology of CD. Existing results are consistent with two possibilities: (i) MAP
infection could be the cause of Crohn’s in patients who are selectively exposed to this organism or
genetically susceptible or (ii) MAP, which is a relatively common dietary organism, may selectively
colonise the ulcerated mucosa of CD patients but it does not initiate or perpetuate intestinal
inﬂammation (Naser et al., 2004).
Initially, similarities were noted between chronic idiopathic granulomatous ileocolitis (i.e. the clinical
syndrome now called CD) and mycobacterial infections (Crohn et al., 1932). Interest on MAP as a
possible cause for Crohn’s revived with the culture of MAP from patients with CD (Chiodini et al.,
1984b) and intensiﬁed after the detection of IS900, the MAP-speciﬁc DNA insertion sequence, in
relatively high numbers of patients with CD relative to patients with ulcerative colitis and normal
controls (Sanderson et al., 1992). Ever since, many studies have been carried out to assess the
potential role of MAP in the aetiology of CD. Higher probability of MAP has been reported in patients
with CD. However, MAP has also been reported from non-inﬂammatory bowel disease controls
(Mendoza et al., 2010) while others have been unable to detect MAP in the blood of Crohn’s patients
(Parrish et al., 2009). Effective treatment of Crohn’s patients with antimycobacterial drugs has been
reported in some studies (Borody et al., 2007), while others cannot ﬁnd an effect in randomised
clinical trials with similar antimicrobials (Selby et al., 2007).
A systematic review and meta-analysis of 28 case–control studies comparing MAP in patients with
CD with individuals free of inﬂammatory bowel disease or patients with ulcerative colitis found a
speciﬁc association of MAP with CD (Feller et al., 2007). Another meta-analysis of studies using nucleic
acid-based techniques to detect MAP in patients with CD conﬁrmed that MAP was detected more
frequently from patients with CD compared to those with ulcerative colitis (Abubakar et al., 2008).
Both studies concluded that though association between MAP and CD is established, further studies
are required to determine its pathogenic role. In consistence with these, a recent meta-analysis
(Waddell et al., 2015) appraised the available research (128 papers) on the zoonotic potential of MAP
and conﬁrmed a signiﬁcant positive association for CD (odds ratio range 4.3–8.4). The latter authors
also concluded that knowledge gaps exist and therefore current evidence is not sufﬁcient to establish a
causal path.
MAP has also been related to an increasing number of diseases: Blau syndrome (Dow and
Ellingson, 2010), type 1 diabetes (Sechi et al., 2008; Rosu et al., 2009; Cossu et al., 2011a),
Hashimoto thyroiditis (Sisto et al., 2010; Pinna et al., 2014) and multiple sclerosis (Cossu et al., 2011b;
Sechi and Dow, 2015). However, in these cases, the so far circumstantial isolation of MAP does not
add to the zoonotic potential of MAP. It rather supports the hypotheses that these diseases favour
survival and opportunistic growth of MAP in the human gut.
Although a causal link between MAP and CD has not yet been proven concerns are being expressed
and, for example, the UK Food Standards Agency has appealed for strategies to further minimise
human exposure to MAP (Rubery, 2001), in addition the ﬁnding of Viable MAP in powdered infant
formula (Botsaris et al., 2016) is worrying.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
Antibiotic treatment is not practiced in MAP-infected animals because it is not cost effective. It
could be an option, as a means to forestall progression of infection, for selected animals of high
genetic value, exceptional production or sport and pet animals.
Susceptibility testing of MAP to 11 antimicrobial drugs in vitro revealed that the organism is most
susceptible to macrolides, while ﬁrst-line antituberculosis (ethambutol and isoniazid) or antileprosy
drugs (dapsone and clofazimine) are not effective with the exception of the rifampicin family (Krishnan
et al., 2009). Gallium nitrate also has in vitro activity against MAP isolates (Fecteau et al., 2011).
However, in vitro drug susceptibility often fails to predict the in vivo efﬁcacy of treatments (Grifﬁth,
2007). Drugs that have been used to treat MAP infections are isoniazid, clofazimine (St Jean, 1996)
and the most promising appears to be monensin (Brumbaugh et al., 2000).
AHL assessment on paratuberculosis
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2017;15(7):4960
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Within infected herds/ﬂocks, animals are exposed to and acquire MAP infection early in their life.
Young animals are more susceptible to infection and susceptibility decreases with age (Kostoulas et al.,
2010). For example, calves are more susceptible in the ﬁrst year of their life (Mortier et al., 2015). The
majority of infected animals in a herd will be in the early infection stages and the proportion of animals
that can be detected by diagnostic tests seriously underestimate the prevalence of infection in the
herd (i.e. the ‘tip of the iceberg’ (Whitlock and Buergelt, 1996)). The disease is more insidious in small
ruminant ﬂocks/herds, than in bovine herds with the incubation period being usually at least 1 year.
Faecal shedding usually precedes clinical signs with the age of onset of faecal shedding and clinical
disease varying with the dose, age at infection, and herd management factors. The typical range for
clinical disease is 2–7 years of age; however, in some heavily infected goat and deer herds clinical
infection and faecal shedding occur as early as 1 year of age. However, regardless the host species the
true morbidity and mortality rates are rarely reported because the exact duration of the latent infection
period, the infectious period and the time that MAP can persist in healthy carriers have not been
quantiﬁed.
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
Sparse information exists on the survival of MAP in the environment but it is clear that MAP can
survive in the environment for a long time as it has been shown in studies investigating its survival and
the levels of contamination in and around ruminant farms (Waddell et al., 2016). Protected from
sunlight – MAP like all mycobacteria is sensitive to ultraviolet light (sunlight) – it survived for up to
55 weeks in a dry fully shaded environment. Water and sediment behind dams prolongs survival times
while dry soil, changes in ambient temperature, pH < 7.0, high ammonia levels and low iron contents
shortens its survival (Whittington et al., 2004, 2005). If vegetation is removed and shading is limited,
then survival is reduced to a few weeks (Eppleston et al., 2014). Water reservoirs may play signiﬁcant
role in MAP infection on farms (Singh et al., 2013). Animals raised in rich organic soil pose a higher
probability of acquiring the infection from the environment probably due to the adsorption of MAP to
clay content (Dhand et al., 2009).
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
The primary route of transmission is the faecal–oral route (Sweeney, 1996). Faecal contamination of
the udder or the calving environment is a main risk factor for neonatal infection (Collins et al., 1994).
MAP can be also excreted in milk/colostrum (Streeter et al., 1995) and shedding depends on the
severity of MAP infection and lactation stage with higher risk observed in early than mid or late
lactation (Stabel, 2008). In utero transmission can also occur and the risk increases with infection
stage (Whittington and Windsor, 2009). MAP can also be excreted in semen but data on transmission
via semen are sparse (Ayele et al., 2004). Transmission is considered to occur primarily from cows to
calves, which are considered most susceptible. Calf-to-calf transmission has been described (van
Roermund et al., 2007), and cow-to-cow transmission may take place but remains mainly undetected
because delayed exposure results in lower incidence of detectable cases (Espejo et al., 2013). In utero
infections occur in cattle (Sweeney et al., 1992; Whittington and Windsor, 2009) and have been
reported in goats as well (Stehman, 1996). A study by Van Kooten et al. (2006) showed that 90% of
clinically affected deer had an infected fetus.
Cross-species transmission exists with different strains of MAP showing preference to different
hosts: type I or S strains are predominantly isolated from sheep and less commonly from deer and
cattle, type II or C strains have a broad host range but frequently infect cattle, goats and deer and
less commonly sheep. Finally, type III strains represent an intermediate type and are predominantly
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isolated from sheep and goats (Stevenson, 2015). Cross species transmission between wild and
domestic ruminants has also been indicated (Fritsch et al., 2012).
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
If MAP is transmitted to humans, the transmission may occur via ineffectively pasteurised milk
(O’Reilly et al., 2004), beef (Alonso-Hearn et al., 2009) or water (Pickup et al., 2005, 2006; Beumer
et al., 2010; Rhodes et al., 2014). The overall prevalence in beef is deemed to be low (Okura et al.,
2010), but reduction due to cooking has not been extensively studied. One study estimated that long
cooking times are required for more than two log10 bacterial reductions (Hammer et al., 2013). The
concentrations in milk are most often considered to be within reach of pasteurisation. However,
experimental studies indicate that if large numbers of MAP are present in milk the organism may not
be completely inactivated through pasteurisation and viable MAP has been found in retail pasteurised
milk (Carvalho et al., 2012). A systematic review of the contamination of food products concluded that
pasteurised milk is not always MAP free, and it cannot be ruled out that meat and meat products
contain MAP (Eltholth et al., 2009). Survival of MAP has also been documented in yoghurt after
artiﬁcial inoculation of pasteurised milk (Van Brandt et al., 2011). If MAP is conﬁrmed as a zoonotic
pathogen, further studies are required to better characterise the routes of transmission to humans.
Speed of transmission
Due to the poor sensitivity of the tests during the long latent period, there is a scarcity of studies
aiming to quantify the within herd dynamics of MAP infection. van Roermund et al. (2007) reported
transmission rates of 2.7 [1.1, 6.6] new calf infections per infectious cow, and 0.9 [0.1, 3.2] new
infections per infectious calf. However, their experimental setting did not mimic a modern dairy farm
and results cannot be directly extrapolated to other conditions.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
The presence of MAP infection has been reported in most Member States (MS). Speciﬁcally, MAP
has been reported in Austria (Dreier et al., 2006), Belgium (Boelaert et al., 2000), Bulgaria
(Kuiumdzhiev, 1950), Croatia (Cvetnic et al., 2012), Cyprus (Liapi et al., 2011), the Czech Republic
(Pavlık et al., 1994), Denmark (Nielsen and Toft, 2014), Estonia (Nielsen and Toft, 2009) Finland
(Kulkas, 2007), France (Marce et al., 2011), Germany (Donat et al., 2016), Greece (Angelidou et al.,
2014), Hungary (Ronal et al., 2015), Ireland (Kennedy et al., 2016), Italy (Cenci-Goga et al., 2010),
Lithuania (Nielsen and Toft, 2009), Luxembourg (Fernandez-Silva et al., 2012), the Netherlands
(Muskens et al., 2003), Poland (Szteyn and Wiszniewska-Laszczych, 2012), Portugal (Mendes et al.,
2004), Slovakia (Mucha et al., 2009), Slovenia (Ocepek et al., 2002), Spain (Dieguez et al., 2009),
Sweden (Frossling et al., 2013) and the UK (Woodbine et al., 2009). No data exist for Latvia, Malta
and Romania. Reports among the MS are not comparable due to the variation in the type of studies
and in the diagnostics used for MAP detection (see Section 3.1.1.2).
Nielsen and Toft (2009) summarised the prevalence of paratuberculosis for dairy cattle, sheep and
goats in Europe (Nielsen and Toft, 2009). The true within-herd prevalence in cattle may be 20% and
was at least 3–5% in several member states. Herd-level prevalence was probably ≥ 50%. Valid
prevalence estimates are scarce for sheep or goats. An extensive study in Cyprus estimated that there
was at least one infected sheep in 60.8% (95% CI: 42.3; 78.8%) and at least one infected goat in
48.6% (30.4; 68.5%) of the ﬂocks. Within infected ﬂocks, the true prevalence of MAP infection was
estimated at 24.6% (16.3; 33.3%) and 23.1% (15.5; 33.6%) in sheep and goats, respectively (Liapi
et al., 2011). A study on the seroprevalence of MAP in central Italy revealed that 73.7% of the sheep
ﬂocks had at least one seropositive animal and the mean seroprevalence was 6.29% (Anna Rita et al.,
2011). A ﬂock-level prevalence of 63% and a mean within-ﬂock prevalence of 6.6% was found in
French goats (Mercier et al., 2010).
There are not sufﬁcient data to prove disease freedom or near-zero prevalence in any member
state. Some countries such as Sweden may have a low prevalence in cattle, but claims to support
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disease freedom (Frossling et al., 2013) are not based on sampling and testing schemes designed and
carried out to prove disease freedom.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Control tools
Parameter 2 – Existence of control tools
Tests for paratuberculosis can be divided in those that detect the organism and those that assess
the host response to MAP infection. An extensive description of these is in Section 3.1.4.1, and
Tables 6, 7 and 8 below. Available diagnostic tests are of imperfect sensitivity and speciﬁcity (although
the latter is often close to 100%). The sensitivity of most of the tests is poor at the early infection
stages and increases with disease progression (Nielsen and Toft, 2008). Nonetheless, such tests can
and have been used for disease control. Currently, available control strategies include management
interventions to improve calf hygiene, test and cull strategies and vaccination (Al-Mamun et al., 2016).
The ﬁrst two of them require long and dedicated efforts from the dairy producers (Groenendaal et al.,
2015) and if combined exhibit a synergistic effect. An extensive description of available control tools is
provided in Section 3.1.4 below.
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
Paratuberculosis is present in most of the member states. The reporting of the prevalence studies
that have been carried out is poor leading to estimates that are not comparable (Nielsen and Toft,
2009). An extensive list of the prevalence estimates, either apparent or true is given in Tables 2–5 and
is discussed in detail in Section 3.1.1.2 Parameter 1. Additional information on the presence of MAP in
the MSs is reported in Section 3.1.1.7.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
Paratuberculosis has major consequences in the subclinically infected and, especially, the clinically
affected animals, leading to decreased and suboptimal productive life due to reduced milk yield
(Lombard, 2011), body weight and slaughter value (Hutchinson, 1996), fertility (Johnson-Ifearulundu
et al., 2000; Kostoulas et al., 2006a; Marce et al., 2009) and, thus, increased rate of premature
voluntary culling. In many species, lowered age of onset linked with increased prevalence and the loss
of young animals increases the overall cost of paratuberculosis (Smith, 1998). When considering the
cost of MAP infection, it is important to point out that typical ‘losses’ are in the form of potential or
unrealised revenue which are easier for producers with high prevalence herds selling cattle with actual
disease to see than for producers with low prevalence herds or culling animals for reasons not being
attributed to the presence of paratuberculosis. MAP-infected cattle have been shown to be at twice the
risk of being culled compared with uninfected herd mates even when producers were not aware of
their infection status (Lombard, 2011).
In two MAP-affected dairy herds (a total of 1048 cows), faecal culture positive cows produced $276
less in milk income per lactation than cows that were faecal culture negative and were 3.0 (1.6–5.8)
times more likely to be culled than faecal culture negative cows (Raizman et al., 2007). A recent
meta-analysis (McAloon et al., 2016) of studies on the impact of MAP on milk productivity provided a
pooled estimate of 5.9% reduction in the milk yield associated with faecal culture or polymerase chain
reaction (PCR) positivity. Interestingly, milk production can initially be higher in infected animals before
it slowly decreases (Nielsen et al., 2009) and cows have been found to produce more milk before their
ﬁrst positive test when compared to their negative herd mates (Smith et al., 2016). Nielsen et al.
(2009) found that MAP associated milk-losses depended on the ELISA proﬁle of dairy cattle as deﬁned
through repeated testing and proposed that repetitive testing schemes, combined with milking records,
can be a useful management tool for the early identiﬁcation of animals that experience or are likely to
experience milk loss, in the near future (Nielsen et al., 2009).
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The stage of MAP infection inﬂuences the impact on body weight and slaughter value. Kudahl and
Nielsen (2009) directly assessed the slaughter value paid to the farmers for carcases with different
combinations of test result and anatomopathological information. They estimated that the slaughter
weight was reduced by 5–15% depending on the stage of infection. Lower quality further reduced
carcass value: cows with MAP antibodies and MAP detected in faeces had a reduction of 17% in
slaughter value. If they also had enteritis and oedema, the slaughter value was reduced by another
31% (i.e. an almost 50% reduction in the slaughter value). Benedictus et al. (1987) estimated the lost
value at slaughter to 25–30% in animals with clinical disease. Raizman et al. (2009) recorded total
losses of $441 in two dairies (1,048 cows) in culled culture-positive compared to cultured-negative
cows with most of this loss being associated with premature culling and reduced beef value.
In the European Union (EU) (the UK), Pritchard et al. (2017) while using ELISA tests in a
paratuberculosis control programme, and positive results for MAP in their lifetime as the basis for
paratuberculosis infection risk allocation, demonstrated milk yield losses associated with high-risk (HR)
cows compared with low-risk (LR) cows in lactations 1, 2 and 3 for mean daily yield of 0.34, 1.05, and
1.61 kg; and accumulated 305-day yields of 103, 316 and 485 kg, respectively. The total loss was 904
kg over the ﬁrst three lactations. Protein and fat yield losses were likewise signiﬁcant, but primarily a
feature of decreasing milk yield. They observed similar trends for both test-day and lactation-average
somatic cell count measures with higher somatic cell counts from medium- and high-risk cows
compared with LR cows, and differences were in almost all cases signiﬁcant. Likewise, mastitis
incidence was signiﬁcantly higher in HR cows compared with LR cows in lactations 2 and 3. They
noted that they expected their results to be conservative, as some animals that were considered
negative could have become positive after the timeframe of the study, particularly if the animal was
tested when relatively young and that test positive cows and/or the worst-affected animals would be
culled as part of the paratuberculosis control programme. Results from this study indicate that HR
cows were associated with detrimental effects on both production and health.
Estimates on the total annual cost per cow vary from 22 USD$ (Ott et al., 1999) to 49 CDN$ (Chi
et al., 2002; Tiwari et al., 2008).
Other losses that have not been quantiﬁed may occur under the radar. International trade
restrictions based on requirements for commodities, such as beef and milk, to originate from animals
free of ‘Paratuberculosis’ occur, but their extent has not yet been described. Similarly, international
livestock trade is also subject to trade restrictions which have not been characterised. For example,
Japan banned live animal imports from Australia in 2016. However, ofﬁcial trade restrictions on
infected herds within Australia has not been found to be helpful in endemically infected areas because
of increased economic and social impact on herds classiﬁed as infected. These restrictions are now
being actively removed from the Australian programme and replaced by transparent risk-based trading
supported by an appropriate herd classiﬁcation system (Geraghty et al., 2014).
Supporting the expectation that cows infected with MAP have a weakened immune system and
therefore are more susceptible to udder infections McNab et al. (1991) and Baptista et al. (2008) have
found signiﬁcant positive associations between SCC and paratuberculosis infection, Dieguez et al.
(2008) reported, higher mastitis incidences and Arrazuria et al. (2014) higher culling due to mastitis in
MAP affected herds when compared with negative herds (McNab et al., 1991; Baptista et al., 2008;
Dieguez et al., 2008; Arrazuria et al., 2014). Also, in animals followed to slaughter, Merkal et al. (1975)
observed that culling due to mastitis was greater in animals with subclinical paratuberculosis (22.6%)
compared with cows negative for paratuberculosis (3.6%) (Merkal et al., 1975). Other studies have
also been reported where paratuberculosis has been associated with reduced lifetime production due
to early culling of animals with and without obvious signs (Benedictus et al., 1987; Hutchinson, 1996;
Lombard, 2011).
In sheep and goats, progression of M. avium subsp. paratuberculosis infection to clinical
paratuberculosis can result in profound weight loss, premature culling and death, with losses
approaching 20% per annum in some sheep ﬂocks in Australia. Negative effects on fertility have
additionally been reported in dairy sheep. Evidence from pathological studies on 12 farms in New
South Wales, Australia, demonstrated that losses from the disease were signiﬁcant and could be
differentiated from other causes of on-farm mortality. That study identiﬁed the disease mortality rate in
2003 on the 12 farms as 8%, resulting in an average reduction in annual income of AU$ 13,715 per
farm, due to an average decrease in gross margin of 8.5% per farm (Windsor, 2015). Economic losses
of 6.4–8.5% in the gross income margin have been recorded on farms where ovine JD mortality
ranged from 6.2% to 7.8% (Bush et al., 2006).
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There is limited summary information about the ﬁnancial impact in the EU. However, if the
prevalence of infected animals with infection that will progress to disease is approximately 5% on
average, and all infected dairy cattle have an average 10% reduction in the last lactation (irrespective
of breed and lactation), and there are 23,400,000 dairy cattle in the EU producing 168,000,000,000 kg
milk/year, i.e. 7,200 kg milk per cow per year, then reduced milk production compared to potential is
36 kg milk per cow per year, or 840,000,000 kg milk per year. With an average 33 EUR/100 L of milk,
this equals approximately €277M/year. Lost milk yield may account for half of the total costs, which
would then be more than €500M for the union per year. This estimate does not include the value of
greenhouse gases (GHG). For example, eradication of MAP from Scotland has been estimated to
reduce the amount of GHG from agriculture by 1% (reduction of 6,900 kt CO2 equivalents by 44
ktCO2 equivalents) (Stott et al., 2010). The estimate does not include the impact on other sectors
such as beef cattle, sheep and goat farming.
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Transmissibility between animals and humans
MAP is not conﬁrmed as a zoonotic agent. However, it equally has not been conﬁrmed that MAP is
not a zoonotic agent. Golan et al. (2009) using zenographs of human foetal gut onto SCID mice have
demonstrated that MAP actively invades the human gut epithelial goblet cells of the small intestine,
inducing severe tissue damage and inﬂammation. These observations indicate that MAP can speciﬁcally
colonise the normal human small intestine and can elicit inﬂammation and severe mucosal damage.
MAP has been extensively investigated as a potential cause of CD in humans.
If conﬁrmed, the most likely routes are consumption of MAP through contaminated milk and beef.
An extensive discussion on the potential zoonotic aspects of MAP, as well as the sources of human
exposure to MAP is given in Sections 3.1.1.3 Parameter 1 and 3.1.1.6 Parameter 2.
Transmissibility between humans
It is not conﬁrmed that MAP is a zoonotic agent, thus any transmission between humans has
therefore not been characterised.
The severity of human forms of the disease
Parameter 5 - Disability-adjusted life year (DALY)
The potential consequences on human health if MAP would be conﬁrmed as the causal agent of CD
are explained below.
CD and ulcerative colitis are the two main components of inﬂammatory bowel disease. It is a
relapsing lifelong inﬂammatory disease that can affect the entire gastrointestinal tract and frequently
presents with abdominal pain, fever and clinical signs of bowel obstruction or diarrhoea with passage
of blood or mucus, or both. Genetic predisposition to the disease has been conﬁrmed. A series of
environmental factors has been implicated in the epidemiology of CD, less women breastfeeding,
improved domestic hygiene and sanitation, availability and quality of (hot) tap water, exposure to air
pollution, consumption of a western diet and increased tobacco use. The latter has been extensively
studied and both active and passive smoking especially if adopted early (even in childhood)
signiﬁcantly increases the risk of developing the disorder (Baumgart and Sandborn, 2012). The highest
annual incidence of CD in Europe has been estimated to 12.7 per 100.000 person-years (Molodecky
et al., 2012).
Current European consensus reached by European Crohn’s and Colitis Organisation (in 2004 and
revised in 2008) lists three forms of active disease: mild, moderate and severe (Dignass et al., 2010).
There is no single standard for diagnosis, but the forms are often characterised by the course of the
disease following different forms of treatment, including steroid therapy. The diagnostic process,
however, is long and complex including many steps. Currently, the Montreal Classiﬁcation scheme is
advocated, which summarised recent developments in disease classiﬁcation and established an
integrated clinical, molecular, and serological classiﬁcation of inﬂammatory bowel disease (Satsangi
et al., 2006).
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The availability of effective prevention or medical treatment in humans
Parameter 6 – Availability of medical treatment and their effectiveness (therapeutic effect and any
resistance)
The aetiology of CD is not known yet and consequently prevention is a challenge and treatment is
mostly palliative. ECCO guidelines for management of CD are given in detail in Dignass et al. (2010),
where management is recommended to be course speciﬁc.
Dignass et al. (2010) do not mention MAP, but if MAP is a cause in some cases of CD, then
antimycobacterial treatment can be of interest. While MAP is generally excluded as a cause by the
gastroenterology society, few studies have been conducted to assess the efﬁcacy of
antimycobacterials. Borody et al. (2007) reported effective treatment of CD using rifabutin, clofazimine
and clarithromycin for a time period from 6 months to 9 years. On the other hand, Selby et al. (2007)
conducted a randomised clinical trial with the same drugs (but in different concentrations) for 2 years
and had a similar relapse in the CD group as in the placebo group. Still, active research is ongoing on
this aspect as some recent publications would indicate (Atreya et al., 2014; Liverani et al., 2014; Naser
et al., 2014; Kuenstner et al., 2015; McNees et al., 2015; Abegunde et al., 2016; Singh et al., 2016;
Davis et al., 2017).
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
Welfare is impaired; in the subclinical phase by reduced immune competence increasing
susceptibility to a range of conditions and especially in the late phases of infection (months to years
after infection), when constant or intermittent diarrhoea develops accompanied by weight loss.
Diarrhoea usually becomes gradually more severe and may lead to emaciation and death. Increased
production loss and/or onset of clinical disease leads to premature culling. In GB, cattle sector
organisations have identiﬁed paratuberculosis as one of the top ten cattle health and welfare issues
(CHAWG, 2012).
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
There are no reports of the impact of MAP infection on biodiversity. MAP infection has been
reported in endangered species (Table 1). There are no studies on the MAP-associated mortality in
these species.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
MAP is rarely reported outside the farming environment though it has been detected also
elsewhere, e.g. drinking water, domestic water tanks, domestic sewage treatment works and domestic
showers (Pickup et al., 2005, 2006; Whan et al., 2005; Beumer et al., 2010; Rhodes et al., 2014).
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
MAP infection has a long latent infection period and consequently is not likely to be used for
bioterrorism. Hence its absence from international bioterrorism lists such as the Bioterrorism
Agents/Diseases list of the CDC (2017) and the Encyclopaedia of Bioterrorism Defense of Australia
Group (Katz and Zilinskas, 2011). Further, it is not included in the Centre for Food Security and Public
Health (CFSPH) list of zoonotic pathogens (CFSPH, 2017).
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
Successful control of MAP infection has been strongly impeded by the lack of sensitive diagnostic
tests that would correctly identify infected animals at the early infection stages, repeated testing
schemes, however, can be used to improve the overall discriminatory power of the diagnostic process
(Nielsen and Toft, 2007).
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Available control strategies include management practices to improve calf hygiene, test-and-cull
strategies and vaccination. A combination of the ﬁrst two effectively reduces the prevalence of MAP
infection (Nielsen and Toft, 2011) but it requires long commitment from the dairy farmers. For
example, the Danish control programme is based on the early identiﬁcation and removal of MAP
shedders through repeated milk-ELISA testing, which is used to categorise the animals into (i) cows
that should be culled before calving or (ii) can be kept but should calve in isolation and (iii) cows in
low-risk of shedding MAP. Clearly, repeated testing schemes aim to closely monitor the course of MAP
infection and, in this way, increase the diagnostic value of existing tests. On the other hand,
vaccination requires less effort and ﬁeld studies have demonstrated that it effectively reduces faecal
shedding (Knust et al., 2013) but restrictions on its use apply mainly due to the fact that vaccination
interferes with the testing for of bovine tuberculosis. Hence, the overall beneﬁts of vaccination depend
on the level of cross reactivity (Groenendaal et al., 2015). Vaccination has been shown to provide
effective disease control in Australia (Windsor et al., 2014) and, while it does not prevent infection or
shedding of MAP, it underpins the national control programme for ovine paratuberculosis along with a
risk-based trading system. MAP can be effectively controlled by for example risk-based measures to
reduce the within-herd spread of MAP (Nielsen and Toft, 2011; Verdugo et al., 2015). Measures to
reduce between-herd spread of MAP is still challenging, but can be established if historical
test-information at the herd-level is combined with animal-level information (Sergeant et al., 2008;
More et al., 2013).
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
Available ante-mortem diagnostic tests for paratuberculosis can be divided into those that detect
MAP and those that assess the immune response of the host. The ﬁrst category includes faecal
smears, culture and PCR tests. The second category includes antibody response (immunoglobulin G
(IgG)) to MAP, delayed type hypersensitivity reaction, lymphocyte proliferation and increased cytokine
(interferon gamma (IFN-c)) production. So far none of the available tests have been certiﬁed by the
OIE (2015).
The lack of affordable, sensitive, ante-mortem diagnostic tests at the early stages of MAP infection
is a major obstacle in the control of paratuberculosis. However, the accuracy of existing tests is
improved with testing and/or interpretation of individual tests at the herd-level though, in this case, its
usefulness diminishes with lowering within-herd prevalence (Nielsen, 2014).
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
The sensitivity and speciﬁcity of existing, commonly used diagnostic tests for paratuberculosis are
given in Tables 6, 7 and 8. However, these estimates are not comparable as they are based on
different reference standard methods and were carried out in different populations with likely
differences in the distribution of the various infection stages. Sensitivity and speciﬁcity estimates are
given separately for cattle, sheep and goats because differences exist between species in the immune
response (Kostoulas et al., 2006b; Verna et al., 2007), the strain distribution and, hence, the infection
stages and the associated test performance.
From a control point of view, prior to the evaluation and subsequent use of diagnostic tests, it is
important to establish the target condition (Nielsen and Toft, 2008), which reﬂects the underlying MAP
status being detected (affected, infectious or infected cows or herds). Effectiveness is related to the
purpose, and few studies have assessed the effectiveness of diagnostic tests for control and disease
prevention. Most studies have been based on simulation models, which suggest that a combination of
test-and-cull and test-and-management is a requirement (Groenendaal et al., 2003; Kudahl et al.,
2007). A test-and-management, test-and-cull combination has also been effective to reduce the
prevalence in a smaller intervention study in the USA (Collins et al., 2010), while a large-scale Danish
study also suggested that test-and-cull might be efﬁcient (Nielsen and Toft, 2011). However, in the
latter study, the effect of biosecurity measures may have been different than what had been reported
by farmers. Nonetheless, it is possible to signiﬁcantly reduce the prevalence, and also remove infection
from individual herds (Verdugo et al., 2015).
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Table 6: Sensitivity (Se) and Speciﬁcity (Sp) of available diagnostic tests for MAP detection in cattle
Test
Category
Diagnostic
Test
Products Se (%) Sp (%)
Infection
stage
Reference
Humoral
immune
response
Serum ELISA IDEXX HerdChek
Parachek
Pourquier
Svanova Various
Moderate
High
High Affected Nielsen and Toft
(2008)
Low
Moderate
High
Moderate
Infectious
Low High Infected
Milk ELISA Antel
Various
29–61 83–100 Infectious
Infected
Nielsen et al. (2002);
Klausen et al.
(2003); Hendrick
et al. (2005)
Cell-
mediated
immunity
DTH
(delayed type
hypersensitivity)
Johnin testing Not
determined
High (>90) Infected Kalis et al. (2002)
IFN-c CSL algorithm
(Bovigam)
13–85 66.1 (63.3–68.8,
95% CI)
Infectious
Infected
Kalis et al. (2003);
Nielsen and Toft
(2008)IDEXX algorithm 67.0 (64.1–69.7,
95% CI)
New algorithm 93.6 (92.0–95.0,
95% CI)
Direct Smears
(acid-fast bacilli)
ZN staining
(Ziehl-Nielsen)
49.0 (low) High Affected Zimmer et al.
(1999)
Conventional
culture
HEYM TREK Low
Moderate
High (~100) Infected Whitlock et al.
(2000); McKenna
et al. (2005)
HEYM 74 (65–82,
95% CI)
High (~100) Infectious Sockett et al. (1992)
HEYM 70 (56–81,
95% CI)
High (~100) Affected Egan et al. (1999)
Radiometric
culture
BACTEC Moderate High Infected
affected
Eamens et al.
(2008)
Tissue culture High High McKenna et al.
(2005)
PCR IMS PCR Moderate
High
High Fang et al. (2002);
Khare et al. (2004)
Real-time High High
Nested High High
ELISA: enzyme-linked immunosorbent assay; PCR: polymerase chain reaction.
Table 7: Se and Sp of available diagnostic tests for MAP detection in sheep
Test
Category
Diagnostic Test Products Se (%) Sp (%)
Infection
stage
Reference
Humoral
immune
response
ELISA IDEXX
Parachek
Svanovir
37 (10–80,
95% CI)
97 (93–99,
95% CI)
Affected
Infectious
Infected
Kostoulas et al.
(2006b)
AGID (agar gel
immunodiffusion)
24.6 (19.1–30.7,
95% CI)
13.8 (8.8–20.3,
95% CI)
100 (99.7–100.0,
95% CI)
Infected
Infected
Sergeant et al.
(2003)
Gumber et al.
(2006)
Cell-
mediated
immunity
DTH (delayed
type
hypersensitivity)
Johnin
testing
55.6 100.0 Perez et al.
(1999)
Direct Faecal culture 16 (2–48,
95% CI)
97 (95–99,
95% CI)
Infected Kostoulas et al.
(2006b)
ELISA: enzyme-linked immunosorbent assay.
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3.1.4.2. Article 7(d)(ii) Vaccination
Killed whole cell vaccines as well as non-attenuated and attenuated live vaccines have been
developed and used against MAP. Subunit vaccines and more recently DNA vaccines have also been
developed (Koets et al., 2006; Roupie et al., 2008). MAP vaccines are administered subcutaneously.
Commercially available vaccines are outlined in Table 9. Vaccination is rarely used for cattle but is
commonly applied in sheep and goats (Windsor, 2015). Restrictions on its use for cattle apply (i.e. it is
prohibited in several European countries such as Denmark, Ireland and Spain), mainly due to the fact
that it interferes with the testing for of bovine tuberculosis. The overall beneﬁts of vaccination depend
on the level of cross reactivity (Groenendaal et al., 2015).
Vaccination against MAP reduces the incidence of clinical disease (Wentink et al., 1994), MAP
shedding (Sweeney et al., 2009) and thus the risk of transmission to uninfected herd-mates (Knust
et al., 2013). Differences may exist in the efﬁcacy between live and killed vaccines but these cannot be
realised due to the variable study designs, vaccination age and indices of vaccine efﬁcacy that have
been used. Further, great heterogeneity exists in the beneﬁts of vaccination probably due to
differences in the prevalence of MAP infection and in the existing biosecurity measures that were or
were not simultaneously applied among published studies (Bastida and Juste, 2011).
Vaccination does not prevent infection and healthy animals remain susceptible to MAP (Larsen and
Miller, 1978). Bastida and Juste (2011) recently reviewed the vaccines that have been experimentally
developed and/or the ones that are commercially available. They also looked into available studies and
afﬁrmed the positive effects of vaccination: reduced microbial contamination risk – through reduced
shedding – and delayed production losses.
Contrary to what constitutes common practice in cattle, vaccination has been extensively applied in
sheep and is one of the two main tools (with the other being a risk-based trading scheme) of the
Australian programme for MAP control in sheep. The Australian experience indicates that vaccination
effects are of increased signiﬁcance in ﬂocks with high prevalence. However, MAP shedding can persist
for many years after vaccination commencement (Dhand et al., 2016). Improved hygiene/management
factors play a key role in the persistence of paratuberculosis (Windsor, 2013) and are required to
reduce transmission.
Table 8: Se and Sp of available diagnostic tests for MAP detection in goats
Test Category Diagnostic Test Products Se (%) Sp (%)
Infection
stage
Reference
Humoral
immune
response
ELISA IDEXX
Parachek
Svanovir
63 (42–93,
95% CI)
95 (90–98,
95% CI)
Affected,
Infectious,
Infected
Kostoulas et al.
(2006b)
AGID (agar gel
immunodiffusion)
39.5 (30.9–48.7,
95% CI)
Gumber et al.
(2006)
Cell-mediated
immunity
DTH (delayed type
hypersensitivity
Johnin
testing
Moderate
High
High Tripathi et al.
(2006)
Direct Faecal culture 8 (2–17,
95% CI)
98 (95–100,
95% CI)
Infected Kostoulas et al.
(2006b)
Tissue PCR Moderate High Tripathi et al.
(2006)
ELISA: enzyme-linked immunosorbent assay; PCR: polymerase chain reaction.
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The availability of the commercial vaccines varies between MS. Gudair has authorisation in Cyprus,
Greece, the Netherlands, Spain and the UK for use in sheep and goats but not in cattle (Videnova and
Mackay, 2012).
3.1.4.3. Article 7(d)(iii) Medical treatments
Not relevant. Antibiotic treatment is not practiced in MAP-infected animals with the exception of
high value animals. A description of available treatments is given in Section 3.1.1.4.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
For herds/regions that are free of MAP infection, biosecurity measures should focus on preventing
the introduction of infected species and/or the co-grazing sharing pastures with infected herds.
Contact with wildlife species should not be ignored. Particularly contact to rabbits has been described
as a factor associated with lack of Paratuberculosis control (Shaughnessy et al., 2013).
Under endemic disease conditions, biosecurity measures should focus on reducing the exposure of
susceptible animals to faeces and/or milk of infectious animals. These efforts should be centred to
young stock – a practice that requires long commitment from the farmers.
Risk assessment tools initially developed in the USA (Rossiter and Burhans, 1996) exist in a variety
of forms, for example, in the Netherlands (Franken, 2005), Denmark (Kudahl et al., 2008) and Ireland
(McAloon et al., 2016). These tools may serve primarily to educate farmers. Pillars et al. (2011)
reported on a 5-year trial covering January 2003 to December 2007 where a JD control programme
was designed speciﬁcally for each participating herd based on the results of an initial risk assessment.
The risk assessment was repeated annually and the control programme updated as needed. Herd risk
assessment scores were used to measure compliance with the control programme and create JD-risk
proﬁles for individual cows raised on the farms. At the end of the 5 years of the cows that were not
exposed to the control programme, 20% were classiﬁed as infected, while only 7% of cows that were
exposed to the control programme were infected. A summary of the available tools to prevent new
infections and manage/minimise the impact of existing infections at the animal and/or herd level can
be found in Sweeney et al. (2012).
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Transmission between herds/ﬂocks occurs primarily via the introduction of infected animals.
Therefore, restrictions of animal movements can be efﬁcient in reducing transmission to MAP-free
establishments and/or in preventing re-introduction of MAP infection. In the Netherlands, use of milk
from herds containing cows with high antibody ELISA values is restricted by some private milk
processors, and most herds cull these animals (Weber et al., 2014). Furthermore, some countries (e.g.
Austria) have restrictions on cattle, sheep, goats and farmed deer with clinical disease: milk from these
animals cannot be used for human consumption and the animals cannot be slaughtered (Khol and
Baumgartner, 2012). Nevertheless, the disease is not regulated at EU level and the extent and nature
of programmes in Europe, which are not ofﬁcial programmes, is very diverse, as summarised in
Nielsen (2009) and Geraghty et al. (2014).
The Australian programme for the control of paratuberculosis initially applied trade restrictions on
infected herds within Australia, a strategy that later was found to be unhelpful due to the increased
economic and social impact. These restrictions are now being replaced by a transparent risk-based
trading supported by a relevant herd classiﬁcation system (Geraghty et al., 2014). However,
Table 9: Commercially available vaccines against MAP
Name/Laboratory Type Species Reference
Mycopar Killed Cattle
Sheep
Uzonna et al. (2003)
Gudair Killed Sheep
Goats
Singh et al. (2007)
Lio-Johne Live Sheep Bastida and Juste (2011)
Neoparasec Live Cattle
Sheep
Goats
Grifﬁn et al. (2009)
Silirum Killed Cattle Stringer et al. (2013)
Phylaxia Killed Cattle Kormendy (1994)
AHL assessment on paratuberculosis
www.efsa.europa.eu/efsajournal 24 EFSA Journal 2017;15(7):4960
restrictions are difﬁcult to apply without possible deﬁnition of a free-status and the lack of reliable
tests.
No ofﬁcial document on movement of livestock with MAP infection exists, but a set of guidelines
has been proposed through the IAP (2016).
Accordingly, importing farms or regions should focus on preventing a further spread of the agent, if
introduced, by limiting the exposure of animals to infectious materials, removing suspicious cases and
the appropriate treatment of manure (IAP 2016).
Moreover, a classiﬁcation of areas into free (surveillance programmes have not shown endemic
infection in 10 years or the agent has been eradicated in the area without MAP detection in the
following 2 years), eradication (surveillance programmes only identify low herd prevalences or the
agent is being eradicated), certiﬁcation (herds or ﬂocks are voluntarily classiﬁed according to their MAP
risk; biosecurity measures, testing and surveillance are in place) and other areas is recommended (IAP,
2016).
3.1.4.6. Article 7(d)(vi) Killing of animals
Culling of test-positive and/or animals with clinical disease appear to have a reducing effect on the
prevalence in cattle populations if an appropriate test-strategy is carried out, and it is assisted by other
measures to reduce transmission. However, killing of animals may not be sufﬁcient if the general
contamination of the environment is maintained (Wolf et al., 2016). Combination of improved calf
hygiene with test-and-cull strategies has proved to effectively reduce the prevalence of MAP infection
(Nielsen and Toft, 2011).
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Carcasses containing MAP can be safely destroyed at rendering plants. However, special precautions
during the disposal of carcasses and other relevant animal by-products due to MAP infection have not
so far been considered because its zoonotic role has not been conﬁrmed.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Direct and indirect costs depend on the type of the control programme and the epidemiological
situation under consideration. The main cost of test-and-cull strategies is the cost of replacing culled
animals and the cost of the – usually repeated – testing scheme. Increased labour and equipment
purchase costs are associated with control actions aiming at improved management/hygiene. The
direct cost of vaccination-based strategies is low but indirect costs lie in the cross reactivity with
tuberculosis testing. So far, assessment of existing control strategies has proven beneﬁcial.
For example, the net beneﬁt of farms in the Alberta Johne’s Disease Initiative was estimated to be
74 CDN$ per cow over the course of a decade. The beneﬁts were lowered to 19 CDN$ if costly
management practices (i.e. the use of pasteurisers) were applied (Wolf et al., 2014). A cost beneﬁt
analysis of vaccination against MAP that adjusted for the cross reactivity with tuberculin tests revealed
direct economic beneﬁts of 8 US$ per adult animal per year and indirect economic costs due to
cross-reactivity of 2 US$. The combination of test-and-cull strategies with improved management
hygiene measures seems to be the most efﬁcient strategy. Groenendaal and Galligan (2003) showed
that improved calf-hygiene strategies were critically important in every paratuberculosis control
programme especially for midsize US dairy farms while test-and-cull strategies alone may not be
efﬁcient in reducing the prevalence of paratuberculosis.
These, of course, depend on the prevalence of MAP infection and the hygiene level. A recent
analysis that was based on data from farms participating in the Danish Control programme, where the
prevalence of paratuberculosis is low (~ 7%), showed that a test-and-cull strategy is on average the
most cost-effective to increase the total net revenue on a farm with low hygiene, but not more
proﬁtable than no action on a farm with average hygiene (Kirkeby et al., 2016). If the objective is to
completely eradicate MAP, the expenses outweigh the beneﬁts of the existing control efforts.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
Disease control measures are likely to be acceptable to society, except that slaughter of
test-positive animals may be of concern to some. Further, farmers may be reluctant to devote the
AHL assessment on paratuberculosis
www.efsa.europa.eu/efsajournal 25 EFSA Journal 2017;15(7):4960
resources required for the implementation of management practices aiming to improve calf hygiene,
despite the fact that the combination of such practices with test-and-cull strategies effectively reduces
the prevalence of MAP infection (Nielsen and Toft, 2011). In addition, improved calf hygiene normally
has beneﬁcial impacts across a range of other conditions affecting calves.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Animal welfare can be affected if offspring is isolated from their dam at birth.
Parameter 2 – Wildlife depopulation as control measure
Wildlife depopulation has not so far been considered as a control measure for MAP.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
No impact on the environment and biodiversity has been identiﬁed, but if wildlife is implicated in
transmission and if regulation of wildlife is deemed needed, then a systematic assessment of the
biodiversity would be required.
MAP is resistant to common disinfectants. Phenolic and cresylic disinfectants are among the most
efﬁcient (Collins, 2003). In a recent study, the application of peracetic acid led to the total elimination
of MAP (Kralik et al., 2014). The latter authors also demonstrated that repeated application of
disinfection procedures are more effective compared to single increases in the concentration or time of
exposure to the disinfectants. There are no reports on the potential impact of residuals in the
environmental compartments (soil, water, feed, manure) as a result of MAP-speciﬁc disinfection
procedures.
There are no reports on mortality in wildlife species due to control measures.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about paratuberculosis (Table 10). The expert judgement was based on Individual and Collective
Behavioural Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA
AHAW Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped
into Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their
Y/N or ‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 10. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 10: Outcome of the expert judgement on the Article 5 criteria for paratuberculosis
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist in
the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal health,
or poses or could pose a signiﬁcant risk to public health due to its zoonotic character
NC
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger to
public and/or animal health in the Union
N
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3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Tables 11 and 12). The proportion of Y, N or na answers are reported,
followed by the list of different supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes:
• If the zoonotic risk of CD is proven, this could cause a signiﬁcant impact.
• Some individual farms have signiﬁcant health and/or production problems (e.g. reduced milk
yield, infertility) where the overt or underlying cause is infection with MAP.
• MAP may be involved in some, but probably not all, cases of CD.
• In Denmark, impact on animal health or production was experienced by approximately half of
dairy farmers.
Supporting No:
• After a review conducted in 2015, no strong evidence was found to conﬁrm the zoonotic role
of paratuberculosis as a causal agent of CD.
• According to the evidence shown in the present opinion, in most of the studies the morbidity
rate and the apparent animal-level prevalence are low.
• The impact on animal health can be considered currently as low considering the whole cattle
sector.
Reasoning supporting the judgement
Supporting Yes:
• There is the potential for a major public health crisis if conclusive evidence were to emerge of
the zoonotic potential of paratuberculosis.
Table 11: Outcome of the expert judgement related to criterion 5 B(i)
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
B(i) The disease causes or could cause signiﬁcant negative effects in the
Union on animal health, or poses or could pose a signiﬁcant risk to
public health due to its zoonotic character
NC 80 20 0
NC: non-consensus; number of judges: 10.
Table 12: Outcome of the expert judgement related to criterion 5 B(iv)
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
B(iv) The disease has the potential to generate a crisis or the disease
agent could be used for the purpose of bioterrorism
NC 30 70 0
NC: non-consensus; number of judges: 10.
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for the
purpose of bioterrorism
NC
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or not
relevant to judge.
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Supporting No:
• The zoonotic role of paratuberculosis is not conﬁrmed thus the potential to generate the crisis
is remote.
• MAP is not listed under pathogens with bioterrorism potential.
3.2.2. Outcome of the assessment of paratuberculosis according to criteria of
Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 10,
paratuberculosis complies with all criteria of the ﬁrst set and with one criterion of the second set,
therefore it is considered to be eligible to be listed as laid down in Article 5 of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about paratuberculosis (Tables 13, 14, 15, 16 and 17). The expert
judgement was based on ICBA approach described in detail in the opinion on the methodology.
Experts have been provided with information of the disease fact-sheet mapped into Article 9 criteria
(see supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement
on each criterion of Article 9, and the reasoning supporting their judgement. The minimum number of
judges in the judgement was ten. The expert judgement was conducted as described in the
methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation of the questions,
see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 13: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for paratuberculosis
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional cases
(irregular introductions) OR present in only in a very limited part of the territory of the Union
N
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread NC
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, including
epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial costs,
mainly related to its direct impact on the health and productivity of animals
Y
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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Table 14: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for paratuberculosis
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic character
AND (at the same time) several Member States or zones of the Union are free of the disease
N
2.1 The disease is moderately to highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne spread NC
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, including
epidemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial costs,
mainly related to its direct impact on the health and productivity of animals
Y
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 15: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for paratuberculosis
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic character Y
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality AND
often the most observed effect of the disease is production loss
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
NC
4 The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related to
its direct impact on certain types of animal production systems
N
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 18 and 19).
The proportion of Y, N or `na0 answers are reported, followed by the list of different supporting views for
each answer.
Reasoning supporting the judgement
Supporting Yes:
• MAP survives well in the environment in water, soil and dust. Infection is normally acquired via
the oral-faecal route, therefore waterborne transmission is highly likely where faecal
contamination of water occurs either directly through defecation into surface waters by
infected bovines (Collins et al., 1994) or water becomes a vehicle for MAP via slurry
contamination (Pickup et al., 2006). A number of human Crohn’s clusters have been linked to
possible MAP presence in water (Van Kruiningen et al., 2005; Pierce, 2009).
• Corner et al. (2004) and Eisenberg et al. (2010) have put forward arguments supporting a role
for aerosol transmission. Eisenberg et al. (2011) have demonstrated intestinal infection
following aerosol challenge of calves with MAP.
Supporting No:
• No airborne/waterborne/vector-borne transmission of paratuberculosis has been described as
yet, even though MAP has been detected in rivers and streams.
• Although these possibilities exist, they are not the main routes of transmission.
Table 16: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for paratuberculosis
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 17: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for paratuberculosis
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL and/or
the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment (If a disease fulﬁls the criteria as in
Article 5, thus being eligible to be listed, consequently category E would apply.)
Y
Colour code: green = consensus (Yes/No).
Table 18: Outcome of the expert judgement related to criterion 2.2 of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
2.2 There be possibilities of airborne or waterborne or
vector-borne spread
NC 30 70 0
NC: non-consensus; number of judges: 10.
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Reasoning supporting the judgement
Supporting Yes:
• In experimental studies, every species that became infected following exposure, including
non-human primates and human fetal gut matured on the backs of mice, have demonstrated
symptoms of CD following infection with MAP. Thus it seems implausible that humans are the
only species that do not become infected with MAP.
• There are a number of cases where Crohn’s symptoms have been resolved in the long term
with antimycobacterial drugs.
• MAP has been isolated from human breast milk.
• MAP has been demonstrated in the blood of some patients with CD.
• MAP has survived pasteurisation in some cases.
• Viable MAP has been isolated from beef of cows with clinical disease and following light
cooking of hamburger patties.
supporting No:
• Up to now, a causal link has not been proven between MAP infection and CD in humans.
Although a signiﬁcant association has been identiﬁed between MAP and CD, knowledge gaps
exist. There is currently insufﬁcient evidence to support a causal relationship. For example,
there is no signiﬁcant association between the prevalence of MAP in livestock and the
incidence of CD in human populations. Similarly, other micro-organisms have been also
associated with CD. It is recognised that not all individuals from which MAP infection has been
detected are susceptible to CD.
3.3.2. Outcome of the assessment of criteria in Annex IV for paratuberculosis for
the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 13–17. According to the
assessment methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the
outcome is ‘Yes’.
A description of the outcome of the assessment of criteria in Annex IV for paratuberculosis for the
purpose of categorisation as in Article 9 of the AHL is presented in Table 20.
Table 19: Outcome of the expert judgement related to criterion 2.2 of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
3 (cat.C) The disease has a zoonotic potential with signiﬁcant consequences
on public health, or possible signiﬁcant threats to food safety
NC 50 50 0
NC: non-consensus; number of judges: 10.
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According to the assessment here performed, paratuberculosis complies with the following criteria
of the Sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control
rules referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment paratuberculosis complies with criterion 2.3,
but not with criteria 1, 2.1 and 2.4 and the assessment is inconclusive on compliance with
criterion 2.2. To be eligible for category A, a disease needs to comply additionally with one of
the criteria of the second set (3, 4, 5a–d) and paratuberculosis complies with criteria 4 and
5b, but not with criteria 3, 5a, 5c and 5d.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment paratuberculosis complies with criteria 2.1, 2.3
and 2.4, but not with criterion 1 and the assessment is inconclusive on compliance with
criterion 2.2. To be eligible for category B, a disease needs to comply additionally with one of
the criteria of the second set (3, 4, 5a–d) and paratuberculosis complies with criteria 4 and
5b, but not with criteria 3, 5a, 5c and 5d.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment paratuberculosis complies with all of them. To
be eligible for category C, a disease needs to comply additionally with one of the criteria of
the second set (3, 4, 5a–d) and paratuberculosis complies with criterion 5b, but not with
criteria 4, 5a, 5c and 5d and the assessment is inconclusive on compliance with criterion 3.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which
paratuberculosis complies.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which
paratuberculosis complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
paratuberculosis. The Article 8(3) criteria are about animal species to be listed, as it reads below:
Table 20: Outcome of the assessment of criteria in Annex IV for paratuberculosis for the purpose
of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
G
eo
g
rap
h
ical
d
istrib
u
tio
n
T
ran
sm
issib
ility
R
o
u
tes
o
f
tran
sm
issio
n
M
u
ltip
le
sp
ecies
M
o
rb
id
ity
an
d
m
o
rtality
Z
o
o
n
o
tic
p
o
ten
tial
Im
p
act
o
n
eco
n
o
m
y
Im
p
act
o
n
so
ciety
Im
p
act
o
n
an
im
al
w
elfare
Im
p
act
o
n
en
viro
n
m
en
t
Im
p
act
o
n
b
io
d
iversity
A N N NC Y N N Y N Y N N
B N Y NC Y Y N Y N Y N N
C Y Y Y Y Y NC N N Y N N
D Y
E Y
AHL assessment on paratuberculosis
www.efsa.europa.eu/efsajournal 32 EFSA Journal 2017;15(7):4960
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.1 According to the
mapping, as presented in table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for paratuberculosis according to the
criteria of Article 8(3) of the AHL are as displayed in Table 21.
Table 21: Main animal species to be listed for paratuberculosis according to criteria of Article 8
(source: data reported in Section 3.1.1.1)
Class Order Family Genus/Species
Susceptible Mammalia Artiodactyla Bovidae Bos taurus, Ovis aries, Bos indicus, Bison
bison, Bubalis bubalis, Bison bison, Capra
ibex, Rupicapra rupicapra, Bos grunniens,
Oreamnos americanus, Capra hircus, Capra
aegagrus hircus, Capra aegagrus ibex, Ovis
orientalis, Ovis Canadensis, Ammotragus
lervia, Ovis aries cameroon dwarf,
Tragelaphus strepsiceros, Saiga tatarica
Camelidae Lama glama, Camelus bacterianus, Camelus
dromedaries, Vicugna pacos, Lama
guanicoe
Cervidae Dama dama, Cervus elaphus, Cervus
Canadensis, Odocoileus virginianus clavium,
Odocoileus hemionus, Dama dama,
Capreolus capreolus, Odocoileus virginianus,
Alces alces, Cervus elaphus nannodes,
Cervus elaphus nelson, Cervus nippon, Axis
axis, Pudu pudu, Rangifer tarandus
Suidae Sus spp., Sus scrofa
Perissodactyla Equidae Equus asinus form. dom., Equus mule,
Equus ferus caballus
Carnivora Canidae Vulpes vulpes, Canis lupus
Felidae Felis catus
Mephitidae Mephitis mephitis
Mustelidae Meles meles, Mustela ermine, Mustela
nivalis
Ursidae Ursus arctos
Procyonidae Procyon lotor
Lagomorpha Leporidae Lepus spp., Oryctolagus cuniculus,
Sylvilagus ﬂoridanus
Rodentia Muridae Mus spp., Apodemus ﬂavicollis, Apodemus
sylvaticus, Rattus norvegicus
Cricetidae Mesocricetus spp., Clethrionomys glareolus,
Microtus agrestis, Sigmodon hispidus
Caviidae Cavia porcellus
1 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, paratuberculosis complies with all criteria of the
ﬁrst set and with one criterion of the second set and therefore can be considered eligible to be
listed for Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, paratuberculosis meets the criteria as in Sections
3, 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and control
rules referred to in points (c), (d) and (e) of Article 9(1) of the AHL.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for paratuberculosis according to Article 8(3) of the AHL are several orders, families and
species of mammals and birds as susceptible and some species of the families Bovidae,
Cervidae and Leporidae as reservoirs, as reported in Table 21 in Section 3.4 of the present
document.
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